PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING ESOPHAGEAL STENOSIS

• US 20170224773A1
• Filed: 08/06/2015
• Published: 08/10/2017
• Est. Priority Date: 08/12/2014
• Status: Active Grant

• Current Assignee: Kagoshima University
• Original Assignee: Kagoshima University
• Inventors: IDO, Akio, TSUBOUCHI, Hirohito, KOMAKI, Yuga
• Granted Patent: US 10,517,928 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 38/18 Growth factors; Growth regulators
• CPC Class Codes: A61K 38/1833 Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
• CPC Class Codes: A61L 2300/252 Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 31/047 Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

According to this invention, the following are provided: a pharmaceutical composition for treating and/or preventing esophageal stenosis, comprising an HGF protein as an active ingredient (wherein the HGF protein may be a polypeptide that is any one of the following: (a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2; (b) a polypeptide comprising an amino acid sequence shown in SEQ ID NO: 2 in which one to several amino acids are deleted, substituted, or added; or (c) a polypeptide comprising an amino acid sequence having at least 90% identity with the amino acid sequence shown in SEQ ID NO: 2; and a stent comprising the pharmaceutical composition.

Claims

1-8. -8. (canceled)

9. A method for treating and/or preventing esophageal stenosis, comprising administering a pharmaceutical composition comprising a hepatocyte growth factor (HGF) protein to a patient.

10. The method according to claim 9, wherein the esophageal stenosis is esophageal stenosis occurring after endoscopic submucosal dissection.

11. The method according to claim 9, wherein the HGF protein is a human HGF protein.

12. The method according to claim 9, wherein the HGF protein is a recombinant HGF protein.

13. The method according to claim 9, wherein the HGF protein is a polypeptide that is any one of the following:

(a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO;

2;

(b) a polypeptide comprising an amino acid sequence shown in SEQ ID NO;

2 in which one to several amino acids are deleted, substituted, or added;

or

(c) a polypeptide comprising an amino acid sequence having at least 90% identity with the amino acid sequence shown in SEQ ID NO;

2.

14. The method according to claim 9, wherein the esophageal stenosis is caused by esophageal ulcer.

15. The method according to claim 9, wherein esophageal ulcer is treated.

16. The method according to claim 9, wherein the HGF protein is comprised in a stent.